Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
--Ended 2017 with a healthy cash position of $380M -- --Recently announced FDA approval and launch of Glatopa ® 40 mg-- CAMBRIDGE, Mass. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended
View HTML
Toggle Summary Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL
--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE ® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of multiple sclerosis (MS)-- --Glatopa 40 mg/mL joins the Sandoz glatiramer acetate injection portfolio
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at the LEERINK Partners 7th Annual Global Healthcare
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2017 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI)--  -- VAI status provides the potential for the near-term FDA approval of Sandoz’s Glatopa 40 mg ANDA-- CAMBRIDGE, Mass. , Jan. 30, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
M281 data shows safety and tolerability with no serious adverse events CAMBRIDGE, Mass. , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported positive top-line
View HTML
Toggle Summary Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 CAMBRIDGE, Mass. , HERTFORDSHIRE, United Kingdom and PITTSBURGH , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL) today announced the
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler , President and CEO, will present at the 36th Annual J. P.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
-- Ended third quarter with a strong cash position of $423M -- CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the third quarter ended September 30, 2017 and provided a corporate update.
View HTML